Keywords
How to Cite
Abstract
Bo’lmachalar fibrillyatsiyasi bilan og’rigan interventsion amaliyot o’tqazgan bemorlar uchun optimal antitrombotik davolash sxemasi klinik jihatdan to’laligicha o’rganilmagan. Oral antitrombotik terapiya va 2 komponentli, shuningdek, uch komponentli antitrombotik terapiya deb nomlanuvchi davolash usullari nazariy jihatdan bo’lmachalar fibrillyatsiyasi tufayli tromboemboliya xavfini va koronar stentlar tufayli tromb rivojlanish ehtimolini kamaytirish uchun tavsiya qilinadi. Biroq, uch komponentli antitrombotik terapiya sezilarli asoratlarga va hayot uchun xavfli bo’lgan qon ketish xavfini sezilarli darajada oshiradi (2). Bu borada olib borilayotgan ilmiy izlanishlar mavjud bo'lib, ular uch komponentli antitrombotik terapiyani muqobil antitrombotik terapiya usullari bilan taqqoslaydi, bu orqali oral antitrombotik terapiya va 2 komponentli terapiyada asoratlar rivojlanish xavfini baholash mumkin.
References
Dominick J. Angiolillo ,,Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention’’
Sahil Khera, ... Deepak L. Bhatt. ,,Percutaneous Coronary Intervention’’
HIROSHI KOIWAYA, NOZOMI WATANABE, NEHIRO KURIYAMA AND YOSHISATO SHIBATA,, Direct Oral Anticoagulants Would Be Best Choice for Atrial Fibrillation Patients After Coronary Stenting: Retrospective Study in a Japanese Population’’ Kurume Medical Journal, 68, 00-00, 2021
Michniewicz E., Mlodawska E., Lopatowska P., Tomaszuk-Kazberuk A. and Malyszko J. : "Patients with atrial fibrillation and coronary artery disease–double trouble". Adv Med Sci 2018; 63: 30.
Capodanno D., Alfonso F., Levine G.N., Valgimigli M. and Angiolillo D.J. : "Dual antiplatelet therapy: appraisal of the ACC/AHA and ESC focused updates". J Am Coll Cardiol 2018; 72: 103.
Dominick J. Angiolillo ,,Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention’’
Michniewicz E., Mlodawska E., Lopatowska P., Tomaszuk-Kazberuk A. and Malyszko J. : "Patients with atrial fibrillation and coronary artery disease–double trouble". Adv Med Sci 2018; 63: 30.
Capodanno D., Alfonso F., Levine G.N., Valgimigli M. and Angiolillo D.J. : "Dual antiplatelet therapy: appraisal of the ACC/AHA and ESC focused updates". J Am Coll Cardiol 2018; 72: 103.
Renad M Altoukhi1, Reema A Alshouimi1, Shahad M Al Rammah1, Mohammed Y Alzahrani2, Abdulaali R Almutairi3, Abdulmajeed M Alshehri2, Osamah M Alfayez4, Majed S Al Yami2, Omar A Almohamme ,,Safety and efficacy of dual versus triple antithrombotic therapy (DAT vs TAT) in patients with atrial fibrillation following a PCI: a systematic review and network meta-analysis.’’ Cardiovascular medicine http://orcid.org/0000-0002-3792-4106
ТУРСУНОВА, Л., & ЖАББАРОВ, О. (2023). ПРИМЕНЕНИЯ САКУБИТРИЛ/ВАЛСАРТАНА У БОЛЬНЫХ С СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ С НИЗКОЙ ФРАКЦИЕЙ ВЫБРОСА.
Tursunova, L. D., & Jabbarov, O. O. (2023). Cardiorenal Syndrome in Patients with Chronic Kidney Disease and Diabetes Mellitus. American Journal of Pediatric Medicine and Health Sciences (2993-2149), 1(9), 332-339.
ТУРСУНОВА, Л., & ЖАББАРОВ, О. (2023). РОЛЬ НАТРИЙУРЕТИЧЕСКИХ ПЕПТИДОВ В ЗАВИСИМОСТИ ОТ СТАДИИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК.
Турсунова, Л. Д., & Жаббаров, О. О. (2023). ЧАСТОТА СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У БОЛЬНЫХ С ДИАБЕТИЧЕСКОЙ НЕФРОПАТИЕЙ САХАРНОГО ДИАБЕТА 2 ТИПА (Doctoral dissertation, Российский национальный конгресс кардиологов 2023).
ТУРСУНОВА, Л., & ЖАББАРОВ, О. (2023). СУРУНКАЛИ БУЙРАК КАСАЛЛИГИ ВА СУРУНКАЛИ ЮРАК ЕТИШМОВЧИЛИГИДА ГИПОТЕНЗИВ ДАВОНИНГ САМАРАСИ.
Жаббаров, О. О., Умарова, З. Ф., Турсунова, Л. Д., Нодирова, Ю. И., Сайдалиев, Р. С., Жуманазаров, С. Б., & Хужаниязова, Н. К. (2023). Ассоциация Полиморфных Маркеров Leu28pro Гена Apoe И Pro12ala Гена Pparg2 При Диабетической Нефропатии У Больных Сд 2 Типа. Central Asian Journal of Medical and Natural Science, 4(1), 146-152.
This work is licensed under a Creative Commons Attribution 4.0 International License.